BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Micro Imaging Technology, Inc. (MMTC) Announces Paradigm Shift in Approach to Providing Software-Based Identification of Microbes


2/13/2013 10:43:56 AM

SAN CLEMENTE, CA--(Marketwire - February 12, 2013) - Micro Imaging Technology, Inc. (OTCQB: MMTC) MIT has developed and patented the MIT 1000, a Microbial Identification System that revolutionizes the pathogenic bacteria diagnostic process and can annually save thousands of lives and tens of millions of dollars in health care costs. This technology, which the Company markets under the name Micro Identification Technologies®, will identify bacteria in minutes at a significantly lower cost per test compared to conventional methods.

Until recently, MIT's Microbial Identification System, the MIT 1000, was comprised of a hardware detection unit, the MIT 1000 Instrument, and a software-based identification component that ran on a dedicated desktop PC with an installed A/D (analog-to-digital) data collection board. This configuration required a bulky, proprietary ribbon cable connected between the MIT 1000 Instrument and the A/D board in the PC. The identification software used two software components: the User Interface program and customer selected collection of MIT Identifiers™. The User Interface program operates the MIT 1000 Instrument and performs microbial identifications using the installed MIT Identifier™ collection. The User Interface program implements the identification component, MIT's proprietary algorithms, necessary for successful identification of a given microbial sample. Updates to the User Interface program or the MIT Identifier™ collection required manual installation of the new version by the end user.

"Today," says MIT's Chief Scientist, David Haavig, PhD, "MIT has transitioned to a new approach that involves a relatively new trend in the computing world commonly referred to as 'the cloud.' The implementation of MIT's proprietary algorithms and the MIT Identifiers™ now resides on high-availability server clusters in geographically disparate data centers." A/D conversion is now performed within the MIT 1000 Instrument and is now connected to a PC via a standard USB cable. Collected data is sent to the identification component via a standard internet connection. This approach allows for protection of MIT's proprietary algorithms and MIT Identifiers™ from reverse engineering, use of a very low cost, general-purpose PC for the User Interface program, and, after a simplified initial installation of the User Interface program software by the end user, push installation of updates. This usage model also inherently allows controlled access to MIT's catalog of Identifiers™, circumventing the need for updating customers' local software whenever new Identifiers™ are added or when the customer chooses to obtain licensing for additional Identifiers™. This design allows for the next version of the system to integrate the general-purpose PC functionality into the MIT 1000 system, providing a completely stand-alone design.

Dr. Haavig concluded, "I am excited about the release of this new technology. It provides tremendous simplification of the software upgrade process and allows for hardening of security."

About: Micro Imaging Technology, Inc.
Micro Imaging Technology, Inc. is a California-based public company that is also registered to do business under the name Micro Identification Technologies. MIT has developed and patented the MIT-1000, a stand-alone, optically-based, software driven system that can detect pathogenic bacteria and complete an identification test, after culturing, in less than five (5) minutes for pennies per test when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean particle-free water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by 2015 according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.

You can find more information about our company and about Micro Identification Technologies™. Please visit our newly enhanced website at www.micro-identification.com.

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, reference MMTC: www.sec.gov.


CONTACT:
Jeffrey Nunez
President and CEO
Email:
Email Contact
Web Site: www.micro-identification.com
Telephone: (949) 388-4546



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->